BRAF and melanoma: The recent identification of activating mutations in B-RAF inover 60% cases of melanoma has offered the first opportunity for a rationaletreatment program [3] and early clinical trials using the RAF kinase inhibitorBAY 43-9006 have been encouraging, being the first positive example of howtargeted therapy can work in malignant melanoma.